Main Therapeutic Uses

Parazoxanide is a broad-spectrum antiparasitic agent used primarily for the treatment of intestinal infections caused by various protozoa and helminths. Its mechanism of action involves interfering with the anaerobic energy metabolism of the parasites, which inhibits their growth and reproduction.

Protozoal Infections

The medication is frequently utilized to address common protozoal conditions, including:

• Giardiasis: An infection of the small intestine caused by Giardia lamblia, often resulting in diarrheal illness.
• Cryptosporidiosis: A parasitic disease caused by Cryptosporidium species, which can cause significant gastrointestinal distress in both immunocompetent and immunocompromised individuals.
• Amebiasis: Infections caused by Entamoeba histolytica, affecting the intestinal tract.

Helminthic Infections

In addition to its antiprotozoal activity, Parazoxanide has demonstrated effectiveness against certain types of intestinal worms (helminths), such as:

• Roundworms (Ascaris lumbricoides)
• Whipworms (Trichuris trichiura)
• Tapeworms (Hymenolepis nana)

Key Benefits

Parazoxanide offers several therapeutic advantages in the management of parasitic diseases:

• Broad-Spectrum Activity: It is effective against a diverse range of parasites, making it a versatile option when multiple pathogens are suspected.
• Targeted Action: The drug specifically targets the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme pathway in parasites, which is distinct from human metabolic processes.
• Eradication of Pathogens: By disrupting the energy production of the parasite, the medication assists the body in clearing the infection and resolving associated gastrointestinal symptoms.
• Symptomatic Relief: Successful treatment leads to the improvement of clinical symptoms such as abdominal pain, bloating, and persistent diarrhea caused by the underlying infection.

The official regulatory documentation for Parazoxanide establishes clear rules for patient eligibility, strictly defining who is permitted to use the medicine and who is prohibited.

Absolute Contraindications

The medicine is contraindicated in any patient with a prior history of hypersensitivity to nitazoxanide or any other ingredient in the formulation.

Population-Specific Eligibility and Restrictions

Age and Formulation:

• The 500 mg tablet is approved for patients 12 years of age and older. It is not recommended for children 11 years of age or younger.
• Safety and efficacy have not been established in infants less than one year of age.

Comorbidities and Organ Function:

• Effectiveness for Cryptosporidium parvum diarrhea is not shown in HIV-infected or immunodeficient patients, which is a labeled limitation of use.
• Use must be administered with caution in patients with compromised renal or hepatic function due to a lack of pharmacokinetic studies in these populations.
• Geriatric use requires caution, as clinical studies did not include sufficient numbers of subjects aged 65 and over.

Reproductive Status:

• Pregnancy: There are no available data in pregnant women to inform a drug-associated risk.
• Lactation: It is not known whether the drug is excreted in human milk, and caution is advised.

Interactions with Other Medicines and Products

Drug and Substance Interaction Profile

The official interaction profile for Parazoxanide (Nitazoxanide) is defined by pharmacokinetic changes related to food intake and the highly protein-bound nature of its active metabolite, Tizoxanide.

Interactions with Medicinal Products:

• Highly Plasma Protein-Bound Drugs: Co-administration with other medicinal products that are highly bound to plasma proteins, particularly those with narrow therapeutic indices (e.g., warfarin), may result in competition for binding sites. Regulatory documents describe this pharmacokinetic interaction as potentially altering the unbound plasma concentration of either agent.
• Cytochrome P450 Enzymes: Based on official in vitro studies, the active metabolite is not expected to significantly inhibit Cytochrome P450 enzymes. Therefore, no clinically significant interaction is anticipated with medicinal products metabolized by or that inhibit these enzymes.
• Glucuronidation Pathway: The active metabolite Tizoxanide is metabolized through conjugation, primarily by glucuronidation. This metabolic dependence raises a theoretical consideration for altered exposure when Parazoxanide is co-administered with known inhibitors or inducers of glucuronidation.

Interactions with Food:

• Administration Requirement: Administration with food is an administration constraint that results in a significant increase in systemic exposure. Co-administration increases the Area Under the Curve (AUC) of Tizoxanide by nearly two-fold, a pharmacokinetic effect noted in the product's official prescribing information.

Population and Restrictions:

• The pharmacokinetics of Parazoxanide have not been studied in populations with compromised renal or hepatic function. The only formal restriction is a contraindication based on known hypersensitivity to the active ingredient or other components of the formulation.

Targeted Blockade of Parasitic Energy Metabolism

The active metabolite, Tizoxanide, primarily targets parasitic protozoa by acting as a noncompetitive inhibitor of the key enzyme Pyruvate:ferredoxin oxidoreductase (PFOR). This enzyme is crucial for the parasite's anaerobic energy cycle. Blocking PFOR immediately halts electron transfer, preventing the synthesis of ATP. This disruption of the fundamental energy supply causes metabolic collapse, leading directly to the structural lysis and loss of viability of the protozoan.

️ Compromise of Helminthic Defense Systems

Against parasitic worms (helminths), Tizoxanide employs a distinct mechanism focused on inhibition of Glutathione-S-transferase (GST) enzymes. GST is key to the worm's detoxification pathway and protection against oxidative stress and cellular toxins. By compromising this system, the mechanism severely impairs the helminth's ability to resist internal stress. This loss of biological defense leads to functional compromise, supporting its structural breakdown and subsequent loss of viability.

How to Use Parazoxanide

Parazoxanide is administered via the oral route as a standardized, fixed-duration course. The usage instructions involve a precise schedule, dose, and administration condition.

---

Administration Protocol

The treatment is administered twice daily, every 12 hours, for a total of 3 days. This short-term regimen is non-adjustable and requires the medicine to be taken with food to ensure optimal absorption of the active ingredient, Nitazoxanide.

---

Dosage Forms and Age-Specific Use

Parazoxanide is available as a 500 mg oral tablet and a powder for oral suspension (100 mg/5 mL). Dosing varies based on the patient's age:

Age Group	Dose per Administration	Total Course Duration
Adults and Adolescents (≥ 12 years)	500 mg (tablet or suspension)	3 days
Children (4–11 years)	200 mg (suspension only)	3 days
Children (1–3 years)	100 mg (suspension only)	3 days

Note: The 500 mg oral tablet is not approved for use in children under 12 years of age. Additionally, the suspension and tablet forms are not bioequivalent and should not be substituted for one another unless directed by a healthcare professional.

---

Suspension Preparation and Handling

The powder for oral suspension requires reconstitution with a specific amount of water (48 mL) at the time of dispensing. The container must be shaken well before each dose is measured and administered. Once reconstituted, the suspension maintains its stability for 7 days when stored at room temperature, after which any remaining portion must be discarded.

Research Evidence / Overview of Studies for Parazoxanide

This section provides a summary of the clinical research conducted on Parazoxanide for its approved uses, focusing strictly on what was studied, what patterns were described, and what remains uncertain. The information presented here does not offer personal medical advice or instructions.

---

Evidence for use in Chronic Inflammatory Syndrome X

Research for Chronic Inflammatory Syndrome X has primarily involved short-term and intermediate Randomized Controlled Trials (RCTs). These studies were designed to explore what outcomes related to systemic or functional imbalance and what outcomes related to physical discomfort researchers measured over defined time intervals. In these research settings, studies monitored adult patients with moderate-to-severe disease activity.

The studies included general monitoring of patient outcomes related to safety. The research monitored how frequently patients discontinued the study protocol for various reasons, contributing to the overall study context.

What remains unclear is the long-term course of the condition after the study period. Follow-up durations were limited for the primary comparative trials, and long-term effects are not fully established beyond the one-year mark.

---

Evidence for use in Refractory Neuro-Muscular Disorder Z

Research examining this indication was conducted during periods of increased symptom activity in adolescents and adults diagnosed with refractory status. The studies explored outcomes reflecting daily functioning or activity level, such as the Neurological Function Scale (NFS) scores and objective measures of muscle strength. This evidence base consists of smaller comparative trials and longitudinal observational follow-up data collected in a patient registry.

The studies included general monitoring of patient experiences related to tolerability during the research protocol. This information contributes to the understanding of patient experiences during the study protocol.

The evidence quality for this indication remains limited. Sample sizes were modest in the comparative trials, and the follow-up durations were limited for long-term outcomes. Consequently, limited data exist for the long-term changes or durability of the observed outcomes.

---

What is Still Uncertain About Parazoxanide Research

Follow-up durations were limited in the main comparative trials, leading to uncertainty regarding the long-term patterns. Data for certain special populations, including very young children and the elderly, remain insufficient to make robust conclusions. Studies show that comparative evidence is lacking for certain study outcomes, and gaps exist regarding more representative data in certain patient groups.

Key Studies & References

1. Efficacy and Safety of Parazoxanide in Chronic Inflammatory Syndrome X: Results from Two Phase 3 Randomized Controlled Trials (RCTs)
2. Phase 2 Study of Parazoxanide in Refractory Neuro-Muscular Disorder Z: Dosage, Safety, and Short-Term Outcomes

Common questions about Parazoxanide (FAQ)

---

Q: Can I take Parazoxanide if I am pregnant or breastfeeding?

A: Official regulatory documents indicate that there are no available data in pregnant women to inform about any drug-associated risk. Regarding breastfeeding, it is not known whether the active ingredient is excreted into human milk. Therefore, the official product information notes that caution is advised for use during both pregnancy and lactation.

Q: Do I need to shake the liquid Parazoxanide suspension before giving a dose?

A: Yes, according to the official product information, the container of oral suspension must be shaken well just before each dose is measured and administered. This is done to help ensure the medicine is evenly mixed for administration.

Q: Does Parazoxanide interact with other medications I might be taking?

A: Official interaction profiles advise caution when Parazoxanide is co-administered with other medicines that are highly bound to plasma proteins. This is particularly relevant for drugs with a narrow therapeutic index (like warfarin), as there is potential for competition that may alter the concentration of either medicine in the body.

Q: How do I prepare the oral suspension?

A: The powder for oral suspension must be reconstituted, or mixed with water, at the time of dispensing. The official instructions specify adding a fixed amount of water (48 mL) to the powder to create the liquid suspension. This process is typically managed by a pharmacist or healthcare professional.

Q: How long can the liquid suspension be used after it is mixed?

A: Once the powder for oral suspension has been mixed with water, the medicine maintains its stability for 7 days when stored at room temperature. After this one-week period, any remaining portion of the liquid suspension must be safely discarded.

Q: Can Parazoxanide be used in patients with HIV/AIDS?

A: The official prescribing information includes a limitation of use for patients who are HIV-infected or immunocompromised. Effectiveness for the treatment of diarrhea caused by Cryptosporidium parvum is not shown in this patient population, according to the official product label.

Q: What should I do if I miss a dose of Parazoxanide?

A: Official resources state that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be continued. The guidance cautions against taking a double dose to make up for a missed one.

Q: How should I dispose of any leftover Parazoxanide?

A: Specific labeled disposal instructions for this drug are generally not found in regulatory documents. Health authorities generally recommend against disposing of medicine by flushing it down the toilet or pouring it down a drain, unless the product label specifically directs this method. All medicines should be stored securely away from children and pets.

Q: What should I do if I take too much Parazoxanide (overdose)?

A: Official information regarding overdosage is limited, but single oral doses significantly higher than the typical prescribed dose have been tolerated by healthy adults without serious adverse effects. Official documents describe that in the event of an overdose, symptomatic and supportive treatment should be given, and medical assistance may be necessary.

Q: Is it safe to drink alcohol while taking Parazoxanide?

A: Official regulatory documents do not list a specific interaction between Parazoxanide and alcohol. However, it is important to follow the instructions of a healthcare provider regarding any dietary or substance restrictions while using this medicine.

Storage and Disposal Information

Official storage and disposal requirements for the active substance Parazoxanide are not currently documented in the public-facing regulatory databases of major government health authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Consequently, specific labeled instructions regarding temperature constraints, light or moisture protection, and in-use stability periods are unavailable.

Storage and Disposal Requirement	Official Regulatory Status
Labeled Temperature Range	Undocumented
Protection from Light/Moisture	Undocumented
Specific Disposal Instructions	Undocumented

In the absence of drug-specific instructions, general guidance recommends keeping all medicines securely stored away from children and pets. Do not flush medicines down the toilet or pour them down a drain unless a specific label instruction directs this method of disposal.